Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview (original) (raw)
Gewandter JS, Fan L, Magnuson A et al (2013) Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study. Support Care Cancer 21(7):2059–2066 ArticleCASPubMedPubMed Central Google Scholar
Miaskowski C, Mastick J, Paul SM et al (2018) Impact of chemotherapy-induced neurotoxicities on adult cancer survivors’ symptom burden and quality of life. J Cancer Surviv 12(2):234–245 ArticlePubMed Google Scholar
Seretny M, Currie GL, Sena ES et al (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 155(12):2461–2470 ArticlePubMed Google Scholar
Molassiotis A, Cheng HL, Leung KT et al (2019) Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav 9:e01312 ArticlePubMedPubMed Central Google Scholar
Bulls HW, Hoogland AI, Kennedy B et al (2019) A longitudinal examination of associations between age and chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer. Gynecol Oncol 152(2):310–315 ArticlePubMed Google Scholar
Hershman DL, Till C, Wright JD et al (2016) Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in southwest oncology group clinical trials. J Clin Oncol 34(25):3014–3022 ArticleCASPubMedPubMed Central Google Scholar
Raphael MJ, Fischer HD, Fung K et al (2017) Neurotoxicity outcomes in a population-based cohort of elderly patients treated with adjuvant oxaliplatin for colorectal cancer. Clin Colorectal Cancer 16(4):397–404 e391 ArticlePubMed Google Scholar
Argyriou AA, Polychronopoulos P, Koutras A et al (2006) Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? Support Care Cancer 14(3):223–229 ArticlePubMed Google Scholar
Nurgalieva Z, Xia R, Liu CC, Burau K, Hardy D, Du XL (2010) Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung cancer. Am J Ther 17(2):148–158 ArticlePubMed Google Scholar
Cox-Martin E, Trahan LH, Cox MG, Dougherty PM, Lai EA, Novy DM (2017) Disease burden and pain in obese cancer patients with chemotherapy-induced peripheral neuropathy. Support Care Cancer 25(6):1873–1879 ArticlePubMedPubMed Central Google Scholar
Schneider BP, Li L, Radovich M et al (2015) Genome-wide association studies for taxane-induced peripheral neuropathy in ECOG-5103 and ECOG-1199. Clin Cancer Res 21(22):5082–5091 ArticleCASPubMedPubMed Central Google Scholar
Cao Y, Zhang G, Wang P et al (2017) Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer. BMC Gastroenterol 17(1):2 ArticleCASPubMedPubMed Central Google Scholar
Zhang X, Jiang LP, Yin Y, Wang YD (2014) XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis. Tumor Biol 35(6):5637–5645 ArticleCAS Google Scholar
Savas S, Kim DY, Ahmad MF, Shariff M, Ozcelik H (2004) Identifying functional genetic variants in DNA repair pathway using protein conservation analysis. Cancer Epidemiol Biomark Prev 13(5):801–807 CAS Google Scholar
Whitehouse CJ, Taylor RM, Thistlethwaite A et al (2001) XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair. Cell. 104(1):107–117 ArticleCASPubMed Google Scholar
Song X, Wang S, Hong X et al (2017) Single nucleotide polymorphisms of nucleotide excision repair pathway are significantly associated with outcomes of platinum-based chemotherapy in lung cancer. Sci Rep 7(1):11785 ArticleCASPubMedPubMed Central Google Scholar
Custodio A, Moreno-Rubio J, Aparicio J et al (2014) Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study. Ann Oncol 25(2):398–403 ArticleCASPubMed Google Scholar
Johnson C, Pankratz VS, Velazquez AI et al (2015) Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients. J Neurol Sci 349(1–2):124–128 ArticleCASPubMedPubMed Central Google Scholar
Hertz D, Kidwell K, K. V, D. S, NL. H. (2017) Association of systemic paclitaxel concentrations with severity and progression of paclitaxel-induced peripheral neuropathy. San Antonio Breast Cancer Symposium. 2017.
Boora GK, Kanwar R, Kulkarni AA et al (2016) Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance). Cancer Med 5(4):631–639 ArticleCASPubMedPubMed Central Google Scholar
Abraham JE, Guo Q, Dorling L et al (2014) Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel. Clin Cancer Res 20(9):2466–2475 ArticleCASPubMed Google Scholar
Lam SW, Frederiks CN, van der Straaten T, Honkoop AH, Guchelaar HJ, Boven E (2016) Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients. Br J Cancer 115(11):1335–1342 ArticleCASPubMedPubMed Central Google Scholar
Boora GK, Kulkarni AA, Kanwar R et al (2015) Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance). J Neurol Sci 357(1–2):35–40 ArticleCASPubMedPubMed Central Google Scholar
Eckhoff L, Feddersen S, Knoop AS, Ewertz M, Bergmann TK (2015) Docetaxel-induced neuropathy: a pharmacogenetic case-control study of 150 women with early-stage breast cancer. Acta Oncol 54(4):530–537 ArticleCASPubMed Google Scholar
Kus T, Aktas G, Kalender ME et al (2016) Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. OncoTargets and Ther 9:5073–5080 ArticleCAS Google Scholar
van Rossum AGJ, Kok M, McCool D et al (2017) Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy. Oncotarget. 8(69):113531–113542 PubMedPubMed Central Google Scholar
Hertz DL, Roy S, Jack J et al (2014) Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy. Breast Cancer Res Treat 145(1):245–254 ArticleCASPubMedPubMed Central Google Scholar
Stock W, Diouf B, Crews KR et al (2017) An inherited genetic variant in CEP72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia. Clin Pharmacol Ther 101(3):391–395 ArticleCASPubMed Google Scholar
Wright GEB, Amstutz U, Drogemoller BI, et al. Pharmacogenomics of vincristine-induced peripheral neuropathy implicates pharmacokinetic and inherited neuropathy genes. Clin Pharmacol Ther. 2018;105(2):402-410
Gutierrez-Camino A, Martin-Guerrero I, Lopez-Lopez E et al (2016) Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population. Pharmacogenet Genomics 26(2):100–102 ArticleCASPubMed Google Scholar
Zgheib NK, Ghanem KM, Tamim H et al (2018) Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study. Pharmacogenet Genomics 28(8):189–195 ArticleCASPubMed Google Scholar
Kelley MR, Wikel JH, Guo C et al (2016) Identification and characterization of new chemical entities targeting apurinic/apyrimidinic endonuclease 1 for the prevention of chemotherapy-induced peripheral neuropathy. J Pharmacol Exp Ther 359(2):300–309 ArticleCASPubMedPubMed Central Google Scholar
Kulkarni AA, Boora G, Kanwar R et al (2015) RWDD3 and TECTA variants not linked to paclitaxel induced peripheral neuropathy in North American trial Alliance N08C1. Acta Oncol 54(8):1227–1229 ArticlePubMed Google Scholar
Moore AS, Norris R, Price G et al (2011) Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach. J Paediatr Child Health 47(12):875–882 ArticlePubMed Google Scholar
Skiles JL, Chiang C, Li CH, et al. (2018) CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer. Pediatr Blood Cancer 65(3).
Moreau P, Pylypenko H, Grosicki S et al (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12(5):431–440 ArticlePubMed Google Scholar
Egbelakin A, Ferguson MJ, MacGill EA et al (2011) Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 56(3):361–367 ArticlePubMed Google Scholar
Campo C, da Silva Filho MI, Weinhold N et al (2018) Bortezomib-induced peripheral neuropathy: a genome-wide association study on multiple myeloma patients. Hematol Oncol 36(1):232–237 ArticleCASPubMed Google Scholar
Guilhaumou R, Solas C, Bourgarel-Rey V et al (2011) Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity. Cancer Chemother Pharmacol 68(6):1633–1638 ArticleCASPubMed Google Scholar
Favis R, Sun Y, van de Velde H et al (2011) Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenet Genomics 21(3):121–129 ArticleCASPubMed Google Scholar
Magrangeas F, Kuiper R, Avet-Loiseau H et al (2016) A genome-wide association study identifies a novel locus for bortezomib-induced peripheral neuropathy in european patients with multiple myeloma. Clin Cancer Res 22(17):4350–4355 ArticleCASPubMedPubMed Central Google Scholar
Johnson DC, Corthals SL, Walker BA et al (2011) Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol 29(7):797–804 ArticleCASPubMed Google Scholar
Cibeira MT, de Larrea CF, Navarro A et al (2011) Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide. Leuk Res 35(9):1178–1183 ArticleCASPubMed Google Scholar
Gregg RW, Molepo JM, Monpetit VJ et al (1992) Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 10(5):795–803 ArticleCASPubMed Google Scholar
de Wit R, Roberts JT, Wilkinson PM et al (2001) Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19(6):1629–1640 ArticlePubMed Google Scholar
Nichols CR, Williams SD, Loehrer PJ et al (1991) Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9(7):1163–1172 ArticleCASPubMed Google Scholar
Sprowl JA, Ciarimboli G, Lancaster CS et al (2013) Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci U S A 110(27):11199–11204 ArticlePubMedPubMed Central Google Scholar
Hucke A, Ciarimboli G (2016) The role of transporters in the toxicity of chemotherapeutic drugs: focus on transporters for organic cations. J Clin Pharmacol 56(Suppl 7):S157–S172 ArticleCASPubMed Google Scholar
Chalret du Rieu Q, White-Koning M, Picaud L et al (2014) Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and thrombocytopenia. Cancer Chemother Pharmacol 74(3):571–582 ArticleCASPubMed Google Scholar
Shord SS, Bernard SA, Lindley C et al (2002) Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity. Anticancer Res 22(4):2301–2309 CASPubMed Google Scholar
Ishibashi K, Okada N, Miyazaki T, Sano M, Ishida H (2010) Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study. Int J Clin Oncol 15(1):82–87 ArticleCASPubMed Google Scholar
Albers JW, Chaudhry V, Cavaletti G, Donehower RC (2014) Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 3:CD005228 Google Scholar
Schloss J, Colosimo M, Vitetta L (2016) New insights into potential prevention and management options for chemotherapy-induced peripheral neuropathy. Asia Pac J Oncol Nurs 3(1):73–85 ArticlePubMedPubMed Central Google Scholar
Frederiks CN, Lam SW, Guchelaar HJ, Boven E (2015) Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: a systematic review. Cancer Treat Rev 41(10):935–950 ArticleCASPubMed Google Scholar
Mielke S, Sparreboom A, Steinberg SM et al (2005) Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 11(13):4843–4850 ArticleCASPubMed Google Scholar
Joerger M, von Pawel J, Kraff S et al (2016) Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 27(10):1895–1902 ArticleCASPubMed Google Scholar
Agergaard K, Mau-Sorensen M, Stage TB et al (2017) Clopidogrel-paclitaxel drug-drug interaction: a pharmacoepidemiologic study. Clin Pharmacol Ther 102(3):547–553 ArticleCASPubMed Google Scholar
Matsuo M, Ito H, Takemura Y et al (2017) Increased risk of paclitaxel-induced peripheral neuropathy in patients using clopidogrel: a retrospective pilot study. J Anesth 31(4):631–635 ArticlePubMed Google Scholar
Wilkinson DG (2001) Multiple roles of EPH receptors and ephrins in neural development. Nat Rev Neurosci 2(3):155–164 ArticleCASPubMed Google Scholar
Chhibber A, Mefford J, Stahl EA et al (2014) Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance). Pharm J 14(4):336–342 CAS Google Scholar
Schneider BP, Li L, Miller K, et al. (2011) Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103. ASCO Meeting Abstract 29(15_suppl):1000.
Bergmann TK, Vach W, Feddersen S et al (2012) GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients. Acta Oncol 52(4):871–874 1–3 ArticleCASPubMed Google Scholar
Schneider BP, Lai D, Shen F et al (2016) Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans. Oncotarget. 7(50):82244–82253 ArticlePubMedPubMed Central Google Scholar
Sucheston-Campbell LE, Clay-Gilmour AI, Barlow WE et al (2018) Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci. Pharmacogenet Genomics 28(2):49–55 ArticleCASPubMedPubMed Central Google Scholar
Leblanc AF, Sprowl JA, Alberti P et al (2018) OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. J Clin Invest 128(2):816–825 ArticlePubMedPubMed Central Google Scholar
Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R (2007) Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish randomised trial in ovarian cancer. J Clin Oncol 25(29):4528–4535 ArticleCASPubMed Google Scholar
Hertz DL, Owzar K, Lessans S et al (2016) Pharmacogenetic discovery in CALGB (Alliance) 90401 and mechanistic validation of a VAC14 polymorphism that increases risk of docetaxel-induced neuropathy. Clin Cancer Res 22(19):4890–4900 ArticleCASPubMedPubMed Central Google Scholar
Lenk GM, Szymanska K, Debska-Vielhaber G et al (2016) Biallelic mutations of VAC14 in pediatric-onset neurological disease. Am J Hum Genet 99(1):188–194 ArticleCASPubMedPubMed Central Google Scholar
Garcia-Sanz R, Corchete LA, Alcoceba M et al (2017) Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array. Hematol Oncol 35(4):746–751 ArticleCASPubMed Google Scholar
Richardson PG, Schlossman RL, Weller E et al (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 100(9):3063–3067 ArticleCASPubMed Google Scholar
Anderson KC (2005) Lenalidomide and thalidomide: mechanisms of action--similarities and differences. Semin Hematol 42(4 Suppl 4):S3–S8 ArticleCASPubMed Google Scholar
Ng T, Chan M, Khor CC, Ho HK, Chan A (2014) The genetic variants underlying breast cancer treatment-induced chronic and late toxicities: a systematic review. Cancer Treat Rev 40(10):1199–1214 ArticleCASPubMed Google Scholar
Themistocleous AC, Crombez G, Baskozos G, Bennett DL (2018) Using stratified medicine to understand, diagnose, and treat neuropathic pain. Pain. 159(Suppl 1):S31–S42 ArticlePubMedPubMed Central Google Scholar
Little J, Higgins JP, Ioannidis JP et al (2009) STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. PLoS Med 6(2):e22 ArticlePubMed Google Scholar
Backshall A, Sharma R, Clarke SJ, Keun HC (2011) Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. Clin Cancer Res: an official journal of the American Association for Cancer Research 17(9):3019–3028 ArticleCAS Google Scholar
Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 126(4):663–676 ArticleCASPubMed Google Scholar
Hu S, Huang KM, Adams EJ, Loprinzi CL, Lustberg MB (2019) Recent developments of novel pharmacologic therapeutics for prevention of chemotherapy-induced peripheral neuropathy. Clin Cancer Res
de Andres-Galiana EJ, Fernandez-Martinez JL, Sonis ST (2016) Sensitivity analysis of gene ranking methods in phenotype prediction. J Biomed Inform 64:255–264 Article Google Scholar